Document is current
Any future updates will be listed below
-
Authors
Xie, Lu
Liang, Xin
Xu, Jie
Sun, Xin
Liu, Kuisheng
Sun, Kunkun
Li, Yuan
Tang, Xiaodong
Li, Xianan
Zhan, Xing
Niu, Xiaohui
Guo, Wei
-
Funding
Funding for this research was provided by:
the Research and Development Fund of Peking University People’s Hospital (Clinical Research and Cultivation Program, grant no. RDL2022-37)
Chia Tai TianQing Pharmaceutical Group Co., Ltd. (TQB2858-Ib-02, TQB2858-Ib-02, TQB2858-Ib-02, TQB2858-Ib-02, TQB2858-Ib-02, TQB2858-Ib-02)
- License Information
-
More Information
Article History
Received: 27 June 2023
Accepted: 8 September 2023
First Online: 15 September 2023
Declarations
:
: This study was approved by the Ethical Review Committees of Peking University People’s Hospital and Hunan Tumor Hospital. All the patients provided written informed consent for data collection and research. Ethical approval reference numbers were 2021PHA140-001 and 2021LP00174.
: All those patients had signed informed consent forms for data collection and publication.
: The authors declare no competing interests.
